Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Pipeline Review, H1 2016

Description: Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Pipeline Review, H1 2016

Summary

‘Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Pipeline Review, H1 2016’, provides in depth analysis on Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) targeted pipeline therapeutics.

The report provides comprehensive information on the Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) targeted therapeutics development and features dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G)
- The report reviews Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) targeted therapeutics and enlists all their major and minor projects
- The report assesses Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies
to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents:
List of Tables
List of Figures
Introduction
Report Coverage
Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) Overview
Therapeutics Development
Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Products under Development by Stage of Development
Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Products under Development by Therapy Area
Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Products under Development by Indication
Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Pipeline Products Glance
Early Stage Products
Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Products under Development by Companies
Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Products under Development by Universities/Institutes
Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Companies Involved in Therapeutics Development
Agilvax, Inc.
Bavarian Nordic A/S
Emergent BioSolutions Inc.
F. Hoffmann-La Roche Ltd.
Trellis Bioscience, Inc.
Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Drug Profiles
Monoclonal Antibodies to Inhibit RSV-G and F Proteins for RSV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit RSV-G and RSV-F for RSV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MVA-RSV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
respiratory syncytial virus (virus like particle) vaccines - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
May 23, 2016: Bavarian Nordic Announces Positive Top Line Results from a Phase 1 Trial of a Novel, Broad Spectrum RSV Vaccine in Healthy Adult and Elderly Populations

Aug 18, 2015: Bavarian Nordic Initiates Phase 1 Clinical Trial of MVA-BN in Respiratory Syncitial Virus
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Pipeline Review, H1 2016
Web Address: http://www.researchandmarkets.com/reports/3802778/
Office Code: SCBR2HYR

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic - Single User</td>
<td>☐</td>
<td>USD 3500</td>
</tr>
<tr>
<td>Electronic - Site License</td>
<td>☐</td>
<td>USD 7000</td>
</tr>
<tr>
<td>Electronic - Enterprisewide</td>
<td>☐</td>
<td>USD 10500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World